Composition :

Each 1 ml contains 2 mg Linezolid

Pharmaceutical Dosage Form:

Intravenous infusion 200 mg in 100 ml glass vial

Intravenous infusion 600 mg in 300 ml glass vial

Indications:

Linezomentin is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Linezomentin is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected.

Pneumonia

Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant isolates) or Streptococcus pneumoniae .
Community-acquired pneumonia caused by Streptococcus pneumoniae, including cases with concurrent bacteremia, or Staphylococcus aureus (methicillin-susceptible isolates only) .

Skin and Skin Structure Infections

Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus pyogenes, or Streptococcus agalactiae. Linezomentin has not been studied in the treatment of decubitus ulcers.
Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes.

Vancomycin-resistant Enterococcus faecium Infections

Vancomycin-resistant Enterococcus faecium infections, including cases with concurrent bacteremia.

Dosage &Administration:

For dosage details leaflet available upon request.

Package and Storage:

Carton box containing: 100 ml solution – 300 ml solution in a transparent Overwrapped glass vials insert leaflet
Store at temperature not exceeding 30°C away from light and moisture.